GSK (NYSE:GSK) Updates FY 2026 Earnings Guidance

GSK (NYSE:GSK) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 4.900-5.000 for the period, compared to the consensus EPS estimate of 4.790. The company issued revenue guidance of $44.8 billion-$44.8 billion, compared to the consensus revenue estimate of $45.7 billion. GSK also updated its FY 2031 guidance to EPS.

GSK Price Performance

Shares of GSK traded down $1.00 during trading hours on Wednesday, hitting $52.71. 1,823,186 shares of the company were exchanged, compared to its average volume of 4,678,074. The company has a market capitalization of $106.62 billion, a PE ratio of 13.71, a PEG ratio of 3.31 and a beta of 0.35. GSK has a one year low of $36.75 and a one year high of $61.69. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.79 and a quick ratio of 0.52. The firm has a fifty day simple moving average of $51.67 and a 200-day simple moving average of $53.45.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be paid a $0.4515 dividend. The ex-dividend date is Friday, August 14th. This is a boost from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 annualized dividend and a dividend yield of 3.4%. GSK’s dividend payout ratio is 46.49%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on GSK shares. Royal Bank Of Canada reiterated an “outperform” rating on shares of GSK in a research report on Tuesday, June 9th. Citigroup assumed coverage on shares of GSK in a research note on Friday, July 24th. They issued a “neutral” rating for the company. Weiss Ratings downgraded shares of GSK from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 11th. Jefferies Financial Group upgraded shares of GSK to a “strong-buy” rating in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded GSK from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, GSK presently has an average rating of “Hold” and an average target price of $53.00.

GSK News Roundup

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Second-quarter results exceeded expectations. GSK reported adjusted earnings of approximately $1.34–$1.36 per share versus consensus of $1.27, while revenue reached about $11.14 billion, ahead of the $11.04 billion estimate. Revenue increased 5.3% year over year, helped by vaccines. GSK earnings results
• Positive Sentiment: Cost savings will fund pipeline investment. GSK is targeting approximately $2.52 billion in annual savings by 2029 and plans to reinvest the money in more than 20 late-stage study starts. The strategy is intended to offset upcoming patent expirations and support the company’s 2031 sales ambitions. GSK cost-saving plan
• Positive Sentiment: GSK is expanding its oncology capabilities. The company will invest £400 million in Britain over three years, including a new Cambridge research hub focused partly on cancer medicines. In addition, partner Hansoh Pharmaceutical’s experimental bone-cancer drug met the main goal in a late-stage trial, strengthening the oncology pipeline. GSK and Hansoh cancer drug trial
• Positive Sentiment: The quarterly dividend was raised 2.6%. GSK declared a dividend of $0.4515 per share, implying an annualized yield of roughly 3.4%, with payment scheduled for October 8 to shareholders of record on August 14.
• Neutral Sentiment: Restructuring is strategically positive but operationally disruptive. GSK plans to close its Stevenage R&D site, affecting about 1,800 employees, while moving research activity to Cambridge. The relocation is expected to improve long-term productivity but may involve near-term execution costs. GSK Stevenage R&D closure
• Negative Sentiment: Revenue guidance remains below consensus. Although GSK raised its 2026 EPS outlook to $4.90–$5.00 from a consensus estimate of $4.79, its revenue guidance of about $44.8 billion trails the roughly $45.7 billion analyst expectation. One analyst also downgraded the stock, citing limited further upside after the earnings rally.

Institutional Investors Weigh In On GSK

A number of hedge funds have recently modified their holdings of GSK. Triumph Capital Management acquired a new position in GSK in the 3rd quarter valued at about $40,000. SkyView Investment Advisors LLC purchased a new stake in shares of GSK in the fourth quarter valued at $302,000. Gabelli Funds LLC increased its stake in GSK by 17.8% during the second quarter. Gabelli Funds LLC now owns 7,960 shares of the pharmaceutical company’s stock worth $306,000 after acquiring an additional 1,200 shares during the last quarter. IHT Wealth Management LLC raised its holdings in shares of GSK by 12.1% during the 2nd quarter. IHT Wealth Management LLC now owns 14,736 shares of the pharmaceutical company’s stock valued at $566,000 after buying an additional 1,589 shares during the period. Finally, Brighton Jones LLC purchased a new stake in GSK during the 4th quarter worth approximately $528,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.